What is the recommended starting dose of contraception for a 43-year-old female taking Zopiclone and lorazepam?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Starting Dose of Contraception for a 43-Year-Old Female Taking Zopiclone and Lorazepam

For a 43-year-old female taking Zopiclone 7.5 mg and lorazepam 1 mg BID, a combined hormonal contraceptive (CHC) starting with a monophasic pill containing 30-35 μg of ethinyl estradiol is recommended as there are no significant drug interactions with these medications.

Contraceptive Options and Considerations

Combined Hormonal Contraceptives (CHCs)

  • Many experts recommend starting with a monophasic pill containing 30-35 μg of ethinyl estradiol and a progestin such as levonorgestrel or norgestimate for women without contraindications 1
  • CHCs can be started at any time if it is reasonably certain that the woman is not pregnant 1
  • If started >5 days after menses began, she should abstain from sexual intercourse or use barrier methods (e.g., condoms) for 7 days 1
  • Blood pressure measurement should be performed before initiation 1

Medication Interactions

  • Neither zopiclone (Imovane) nor lorazepam have clinically significant interactions with hormonal contraceptives that would affect contraceptive efficacy 1
  • Psychotropic medications, including benzodiazepines like lorazepam, are classified as Category 1 (no restriction on method use) for all contraceptive methods 1
  • While some benzodiazepines may have altered pharmacokinetics with oral contraceptives, these changes are not clinically significant enough to affect the dosing of either medication 2

Age-Related Considerations

  • At 43 years old, all contraceptive methods are considered U.S. Medical Eligibility Criteria category 1 or 2 (no restriction, or advantages generally outweigh theoretical or proven risks) based on age alone 1
  • Women approaching menopause should continue contraception until menopause or at least until 50-55 years of age 1
  • The noncontraceptive benefits of CHCs include decreased menstrual cramping, reduced blood loss, and protection against endometrial and ovarian cancers 1

Administration Guidelines

Starting the Method

  • CHCs can be initiated immediately (same-day start) if reasonably certain the woman is not pregnant 1
  • If starting >5 days after menses began, use backup contraception for 7 days 1
  • Take one pill at approximately the same time each day 1

Missed Pill Management

  • If one pill is missed (<24 hours late): Take the missed pill as soon as possible and continue regular schedule 1
  • If two or more consecutive pills are missed (>48 hours late): Take the most recent missed pill immediately, continue taking remaining pills as scheduled, and use backup contraception for 7 days 1
  • If pills were missed in the last week of hormonal pills: Omit the hormone-free interval and start a new pack immediately 1

Monitoring and Follow-up

  • Blood pressure should be measured before initiation 1
  • No pelvic exam is required to prescribe oral contraceptive medications 1
  • Follow-up to assess tolerance and address any side effects is recommended

Potential Side Effects and Management

  • Breakthrough bleeding: If it occurs, NSAIDs for 5-7 days may help manage this common side effect 1
  • Nausea: Taking the pill with food or at bedtime may reduce this symptom 1
  • Headaches: Evaluate pattern and severity; migraine with aura would be a contraindication 1

Alternative Options

  • If CHCs are not desired or contraindicated, other options include:
    • Progestin-only pills (POPs): Can be started at any time; if >5 days after menses started, use backup contraception for 2 days (norethindrone/norgestrel) or 7 days (drospirenone) 1
    • Long-acting reversible contraception: Such as intrauterine devices or implants 1
    • Vaginal ring: Releases 15 μg ethinyl estradiol and 120 μg etonogestrel; provides comparable efficacy with simpler regimen 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.